|
重组人凝血因子 在中国血友病A患者的有效性及抑制物产生的观察 |
| |
bsp;HBV, HCV and HIV, FⅧ inhibitor were detected before and after the treatment in 11 of the 30 patients. The detection of FⅧ activities were performed at 10 min and 60 min after the first infusion. Then detected the FⅧ inhibitor in 2 years followup with this 11 patients. Results It was observed that the FⅧ activities at 10 min and 60 min after the first infusion significantly increased, reached the expected value and the hemorrhage was stopped. All of the 30 patients’ bleeding events were stopped after the infusion, so the effectiveness reached 100%. 86.7% patients used less than thrice to stop bleeding. Of all the 30 patients, we used kogenate FS 51 294 u in total with 70 infusions. There was no adverse effect during the medication. Only one patient generated FⅧ inhibitor after 4 weeks. Which indicates that the short term of inbitor generation is 3.3%(1/30). Conclusion Kogenate FS has better efficacy, safety and lower inhibitor generation in Chinese patients with hemophilia A.
Key words： Recombinant factor Ⅷ（Kogenate FS）; Hemophilia A; FⅧ inhibitor上一页 [1] [2] [3] [4] [5] [6] [7] [8] 下一页
上一个医学论文： 白血病患者炎症因子 VEGF表达与易栓状态关系的研究
下一个医学论文： 出血性血小板病患者凝血酶受体GP Ib IX V复合物表达研究
|
|
|
|
|
|
|
您现在的位置： 绿色健康网 >> 医学论文 >> 内科论文 >> 正文